Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
2.41
Jul 10 • 04:00PM ET Dollar change-0.10 Percentage change(-3.98%)
Index
-
Market Cap
54.16M
Enterprise Value
9.60M
Income
-55.99M
Sales
0.00M
Book/sh
3.86
Cash/sh
4.13
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
28
IPO
Mar 28, 2024
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.63
P/C
0.58
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
9.87
Current Ratio
9.87
Debt/Eq
0.56
LT Debt/Eq
0.52
Option/Short
No / Yes
EPS (ttm)
-2.50
EPS next Y
-0.93
EPS next Q
-0.58
EPS this Y
7.69%
EPS next Y
61.25%
EPS next 5Y
-
EPS past 3/5Y
-8.04% -23.10%
Sales past 3/5Y
- -
EPS Y/Y TTM
15.42%
Sales Y/Y TTM
-
EPS Q/Q
14.39%
Sales Q/Q
-
Insider Own
23.35%
Insider Trans
2.59%
Inst Own
49.76%
Inst Trans
11.19%
ROA
-33.71%
ROE
-50.22%
ROIC
-42.62%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
13.65%
SMA50
39.15%
SMA200
77.95%
Trades
Shs Outstand
22.41M
Shs Float
17.23M
52W High
2.79 -13.62%
52W Low
0.96 150.73%
Volatility
3.79% 5.31%
ATR (14)
0.14
RSI (14)
67.32
Beta
0.39
Rel Volume
0.30
Avg Volume
1.35M
Volume
402,913
Perf Week
-3.60%
Perf Month
72.14%
Perf Quarter
111.40%
Perf Half Y
88.28%
Perf YTD
100.83%
Perf Year
104.24%
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
2.51
Price
2.41
Change
-3.98%
Date Action Analyst Rating Change Price Target Change
Jun-02-25Initiated H.C. Wainwright Buy $5
May-28-25Downgrade Leerink Partners Outperform → Market Perform $3
Dec-13-24Downgrade Guggenheim Buy → Neutral
Apr-22-24Initiated Piper Sandler Overweight $20
Apr-22-24Initiated Leerink Partners Outperform $25
Apr-22-24Initiated Guggenheim Buy $24
Jun-25-26 01:53PM
Jun-23-26 10:53PM
01:32PM
07:30AM
May-08-26 07:00AM
04:49PM Loading…
Apr-17-26 04:49PM
Mar-17-26 04:52PM
Mar-09-26 07:00AM
Mar-04-26 07:00AM
Feb-13-26 12:00PM
Feb-05-26 07:00AM
Jan-20-26 07:00AM
Nov-24-25 07:00AM
Nov-05-25 07:00AM
Oct-13-25 04:05PM
07:00AM Loading…
Aug-05-25 07:00AM
Jun-05-25 04:58PM
May-23-25 04:01PM
May-14-25 12:00PM
May-09-25 07:00AM
May-01-25 08:23AM
Apr-03-25 07:00AM
Mar-27-25 07:00AM
Feb-26-25 07:00AM
Feb-03-25 10:00AM
Dec-12-24 04:01PM
Nov-25-24 07:00AM
Nov-07-24 04:01PM
Nov-05-24 07:00AM
Oct-14-24 08:00AM
07:00AM Loading…
Sep-11-24 07:00AM
Aug-13-24 04:28AM
03:32AM
Aug-12-24 10:53PM
04:01PM
Jun-05-24 07:00AM
May-13-24 02:53PM
07:00AM
May-06-24 08:00AM
May-01-24 10:05AM
Apr-14-24 11:37AM
Apr-11-24 08:00AM
Apr-08-24 08:00AM
Mar-27-24 06:55PM
Boundless Bio, Inc. is a clinical-stage oncology company, which is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA. The company was founded by Vineet Bafna, Paul Mischel, Benjamin F. Cravatt, and Jonathan E. Lim on April 10, 2018 and is headquartered in La Jolla, CA.
CEOMr. Zachary D. Hornby
Chief Scientific OfficerDr. Christian Hassig Ph.D.
Ph.D.Dr. Robert C. Doebele M.D.
Senior VP of FinanceMr. David Hinkle
Chief Legal Officer & Corporate SecretaryMs. Jessica Oien J.D.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
TANG KEVIN10% OwnerJul 06 '26Buy2.4927,06267,3842,668,370Jul 08 08:06 PM
TANG KEVIN10% OwnerJul 07 '26Buy2.4815,81039,2092,684,180Jul 08 08:06 PM
TANG KEVIN10% OwnerJul 08 '26Buy2.4614,33835,2712,698,518Jul 08 08:06 PM
CRANDELL KEITH10% OwnerJul 01 '26Option Exercise1.0316,00016,48016,000Jul 06 05:44 PM
CRANDELL KEITH10% OwnerJul 01 '26Sale2.4916,00039,8400Jul 06 05:44 PM
ARCH Venture Fund IX, L.P.10% OwnerJul 01 '26Option Exercise1.0316,00016,48016,000Jul 06 05:43 PM
ARCH Venture Fund IX, L.P.10% OwnerJul 01 '26Sale2.4916,00039,8400Jul 06 05:43 PM
TANG KEVIN10% OwnerJul 01 '26Buy2.4971,612178,3142,631,487Jul 02 07:45 PM
TANG KEVIN10% OwnerJun 30 '26Buy2.5426,03066,1122,559,875Jul 02 07:45 PM
TANG KEVIN10% OwnerJul 02 '26Buy2.499,82124,4542,641,308Jul 02 07:45 PM